Angiotensin-converting enzyme inhibitors (enalapril), β-adrenoblockers (bisoprolol, carvedilol) and angiotensin II receptor blockers (irbesartan) in the treatment of chronic heart failure

Upnitskiy Аleksandr Аbramovich

Abstract Chronic heart failure (CHF) is currently an urgent problem in modern clinical practice, which is associated with a deterioration in the quality of life of patients and an increased risk of mortality due to the development of complications in the cardiovascular system. This fact explains the recommended integrated approach in the treatment of this pathology, among which paramount importance is given to angiotensin-converting enzyme inhibitors (ACE inhibitors) and β-adrenergic blockers. Angiotensin II receptor blockers (ARBs) are used in case of patient intolerance to an ACE inhibitor.

Keywords:chronic heart failure, quality of life, angiotensin-converting enzyme inhibitors, β-adrenergic blockers